Metoclopramidhydrochlorid Noridem (Metoclopramide Hydrochloride)

Metoclopramide works by blocking dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This blockade reduces the brain’s nausea signal and enhances coordinated gastrointestinal muscle activity, leading to faster gastric emptying and reduced episodes of vomiting.

The dose of Metoclopramidhydrochlorid Noridem is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and route of administration. Typical regimens range from single to multiple daily injections, but exact dosing must be individualized by a qualified healthcare professional.

Safety data for Metoclopramidhydrochlorid Noridem during pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks to the fetus or infant and consider alternative therapies when appropriate. Consultation with a maternal‑fetal medicine specialist is advisable.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to Metoclopramide is the serotonin 5‑HT3 antagonist class, such as ondansetron. While ondansetron blocks serotonin receptors and is effective for chemotherapy‑induced nausea, Metoclopramide adds a pro‑kinetic effect by enhancing gastric motility. Choice depends on the clinical scenario, patient tolerance, and risk of extrapyramidal side effects.

Metoclopramidhydrochlorid Noridem should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect from moisture and direct light, and discard any solution that appears discolored or contains particles.

The product is supplied as a sterile injectable solution and is administered by intramuscular or intravenous injection. The route, rate of infusion, and volume are determined by the prescribing clinician based on the indication and patient condition.

Serious risks include extrapyramidal reactions such as acute dystonia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome, a life‑threatening condition characterized by fever, muscle rigidity and autonomic instability. Prompt medical attention is required if any of these symptoms occur.

Metoclopramidhydrochlorid Noridem is contraindicated in patients with known hypersensitivity to metoclopramide, those with pheochromocytoma, severe depression, or a history of extrapyramidal disorders. Caution is also advised for individuals with gastrointestinal obstruction, perforation, or hemorrhage.